GLP-1 via TikTok link: what the science says about telehealth weight loss claims

What did @lesa.glp1pa actually say?

Lisa, a self-identified physician assistant and GLP-1 user, tells her 84K viewers exactly where to get GLP-1 medications online, no insurance required. She says you fill out a health history form, a licensed practitioner reviews it, and your medication ships to your door in seven to ten days with all supplies included.

She frames it as a personal recommendation, not a paid promotion, though the video directs viewers to a bio link and describes a "customer appreciation program" that discounts continued dosing when users check in monthly. That detail matters. A PA steering patients toward a specific telehealth vendor through a trackable bio link, while describing discount incentives for loyalty, carries the hallmarks of an affiliate arrangement, even if that word never appears on screen. Viewers deserve to know whether Lisa has a financial relationship with this company before they fill out any form.

Does the science back this up?

The core process she describes, online intake, licensed prescriber review, and mail-order dispensing, is a legitimate model used by regulated telehealth platforms. But the claim that compounded GLP-1s are equivalent to branded drugs like Ozempic or Wegovy is not supported by current evidence, and she never clarifies which product type she is promoting.

GLP-1 receptor agonists like semaglutide and tirzepatide have robust clinical backing. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide producing up to 22.5% body weight reduction in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4mg reducing body weight by roughly 15% versus placebo. That evidence applies to FDA-approved, brand-name formulations. Compounded versions of these molecules, which many telehealth platforms dispense, have not been tested in equivalent clinical trials. The FDA has explicitly stated it cannot confirm that compounded semaglutide products are safe or effective.

What did they get wrong (or right)?

Lisa gets some things right. Insurance coverage for GLP-1s remains genuinely inconsistent and frustrating. A 2023 analysis by KFF found that coverage varies sharply by plan type and indication, and many patients with legitimate prescriptions are denied. Her experience is not unusual.

She also correctly notes that telehealth platforms require licensed practitioner review before dispensing, which is a legal requirement, not a selling point unique to one vendor.

What she gets wrong, or at minimum glosses over, is the regulatory complexity of what gets shipped. The video is categorized under "peptides" on this platform, which flags a concern. If the product being shipped is a compounded version of semaglutide, that is a meaningfully different product than what was studied in clinical trials. Compounding pharmacies are not required to prove bioequivalence. Saying "your GLP-1" gets shipped to your door obscures whether that product is FDA-approved or compounded, and that distinction matters clinically and legally.

There is also no mention of contraindications. GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in patients with a personal or family history of medullary thyroid carcinoma or MEN2. A form review is not the same as a thorough clinical conversation.

What should you actually know?

If you are considering a telehealth GLP-1 prescription, the process Lisa describes is real and legal, but the details underneath it require scrutiny. A legitimate platform will always disclose whether the dispensed product is FDA-approved or compounded. It will be transparent about prescriber credentials and follow-up protocols. And it will not rely on a monthly check-in incentive program to keep you on medication.

Ask specifically whether the product is brand-name or compounded semaglutide or tirzepatide. Ask which pharmacy fulfills the order and whether it is PCAB-accredited. Ask what happens if you have a side effect between check-ins. GLP-1 medications can cause nausea, vomiting, pancreatitis, and in rare cases more serious events. "No extra fees, no subscriptions" is a pricing structure, not a safety guarantee.

Finally, the FDA placed compounded semaglutide on its shortage list, which temporarily allowed broader compounding. As of early 2025, FDA has signaled that shortage designation may be revisited. The regulatory status of compounded GLP-1s is actively shifting, and a TikTok bio link will not keep you updated on that.